Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.63 |
| ▸ | TP53 | P04637 | 10/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 4/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134580 | 0.89 | MAPT (0.76) | MAPTTP53SMN1; SMN2RXFP1POLB | |
| SCHEMBL22542452 | 0.89 | MAPT (0.79) | MAPTTP53SMN1; SMN2RXFP1POLB | |
| SCHEMBL426251 | 0.88 | MAPT (0.78) | MAPTTP53SMN1; SMN2RXFP1POLB | |
| SCHEMBL19000241 | 0.85 | MAPT (0.62) | MAPTTP53SMN1; SMN2RXFP1POLB | |
| SCHEMBL18999971 | 0.84 | MAPT (0.61) | MAPTTP53SMN1; SMN2RXFP1POLB | |
| SCHEMBL18537653 | 0.83 | ADORA2A (0.68) | MAPTTP53SMN1; SMN2RXFP1POLB | |
| SCHEMBL18999962 | 0.83 | MAPT (0.64) | MAPTTP53SMN1; SMN2RXFP1POLB | |
| SCHEMBL18999961 | 0.83 | TDP1 (0.61) | MAPTTP53SMN1; SMN2RXFP1POLB | |
| SCHEMBL430301 | 0.82 | ADORA2A (0.83) | MAPTTP53SMN1; SMN2POLBADORA2A | |
| SCHEMBL19000337 | 0.81 | TP53 (0.67) | MAPTTP53SMN1; SMN2RXFP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | MAPT 138/4885TP53 3355/4885SMN1; SMN2 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.